Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

Am J Hematol. 2013 Apr;88(4):312-6. doi: 10.1002/ajh.23406. Epub 2013 Feb 28.

Abstract

Iron homeostasis is dysregulated in primary myelofibrosis (PMF), given the high prevalence of anemia, need for red blood cell (RBC) transfusions, and disease-associated inflammatory state. We measured plasma hepcidin levels in 203 consecutive PMF patients at the time of first referral; hepcidin levels were significantly higher as compared to healthy controls (P < 0.0001), and were correlated with hemoglobin of <10 g/dL, RBC transfusion requirement, serum ferritin of >500 µg/L, higher dynamic international prognostic scoring system (DIPSS)-plus risk category, the presence of circulating blasts, age of >65 years, and leukocyte count of <4 × 10(9) /L. Increased hepcidin levels predicted for inferior survival independent of six out of the eight DIPSS-plus prognostic parameters (hazard ratio [HR] = 1.8; P = 0.02), but not when RBC transfusion requirement, hemoglobin of <10 g/dL, or increased serum ferritin were included in the Cox model. Multivariable analysis that considered the four overlapping prognostic variables revealed that increased hepcidin (HR = 1.9; P = 0.03) and increased ferritin (HR = 2.3; P = 0.04), but not hemoglobin of <10 g/dL or RBC transfusion requirement, independently retained their significance for predicting survival. Accordingly, increased levels of both hepcidin and serum ferritin (seen in 29% of patients) predicted inferior survival independent of DIPSS-plus or increased inflammatory cytokine levels (HR = 2.4; P = 0.002), and could be considered in future prognostic models for PMF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimicrobial Cationic Peptides / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Cytokines / blood*
  • Erythrocyte Transfusion
  • Female
  • Ferritins / blood*
  • Hemoglobins / metabolism*
  • Hepcidins
  • Humans
  • Inflammation / metabolism
  • Iron / blood*
  • Leukocyte Count
  • Male
  • Middle Aged
  • Primary Myelofibrosis / blood*
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / therapy
  • Prognosis
  • Proportional Hazards Models
  • Risk Factors
  • Survival Analysis

Substances

  • Antimicrobial Cationic Peptides
  • Biomarkers
  • Cytokines
  • HAMP protein, human
  • Hemoglobins
  • Hepcidins
  • Ferritins
  • Iron